KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Income from Continuing Operations (2018 - 2025)

Vir Biotechnology's Income from Continuing Operations history spans 8 years, with the latest figure at 42923000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 58.96% year-over-year to 42923000.0; the TTM value through Dec 2025 reached 437987000.0, up 16.09%, while the annual FY2025 figure was 437987000.0, 16.09% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 42923000.0 at Vir Biotechnology, up from 163141000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 525254000.0 in Q4 2021 and bottomed at 213717000.0 in Q3 2024.
  • The 5-year median for Income from Continuing Operations is 107773500.0 (2024), against an average of 26574600.0.
  • The largest YoY upside for Income from Continuing Operations was 407.04% in 2022 against a maximum downside of 225.47% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 525254000.0 in 2021, then plummeted by 119.34% to 101603000.0 in 2022, then fell by 14.14% to 115973000.0 in 2023, then rose by 9.82% to 104589000.0 in 2024, then skyrocketed by 58.96% to 42923000.0 in 2025.
  • Per Business Quant, the three most recent readings for VIR's Income from Continuing Operations are 42923000.0 (Q4 2025), 163141000.0 (Q3 2025), and 110958000.0 (Q2 2025).